AAOS 2024: Autologous Chondrocyte Implantation vs. Microfracture for Knee Cartilage Defects .
Costal Chondrocyte-Derived Pellet-Type Autologous Chondrocyte Implantation for Treatment of Articular Cartilage Defect: A Five-Year Follow Up of a Prospective Randomized Trial
This abstract presents the 5-year follow-up results of a previously published prospective randomized controlled trial. 30 patients with an International Cartilage Repair Society (ICRS) grade 3 to 4 chondral defect in the knee were randomized to receive costal chondrocyte–derived pellet-type autologous chondrocyte implantation (CCP-ACI; n=20) or microfracture (MFx; n=10). 25 of these patients were followed-up at 5 years. Outcomes of interest included the Lysholm score, International Knee Documentation Committee (IKDC) score, Knee Injury and Osteoarthritis Outcome Score (KOOS), Visual Analog Scale (VAS) pain score, Magnetic resonance Observation of Cartilage Repair Tissue (MOCART) score, and treatment failure, all assessed at 5 years. In the CCP-ACI group, MOCART, Lysholm and KOOS scores improved significantly from baseline compared the the MFx group. One treatment failure was reported in the MFx group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics